SCHEMBL19089783

SCHEMBL19089783

C=CCOC(=O)Nc1ccc(CCNC(C)=O)cc1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.50
F13A1 P00488 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
ACACB O00763 3/20 0.44
HTT P42858 1/20 0.44
ALDH1A1 P00352 1/20 0.43
LMNA P02545 1/20 0.43
MAPT P10636 1/20 0.43
HPGD P15428 1/20 0.43
PTGS1 P23219 1/20 0.43
BLM P54132 1/20 0.43
HIF1A Q16665 1/20 0.43
HSD17B10 Q99714 1/20 0.43
CNR1 P21554 3/20 0.43
FPR2 P25090 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14349999 0.83 TUBB4A (0.49) KDM4ESMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL8589506 0.82 MEN1 (0.47) KDM4ESMN1; SMN2MEN1KMT2AMAPT
SCHEMBL8867866 0.82 MEN1 (0.47) KDM4ESMN1; SMN2MEN1KMT2AMAPT
SCHEMBL8867871 0.82 MEN1 (0.47) KDM4ESMN1; SMN2MEN1KMT2AMAPT
SCHEMBL9126056 0.81 MEN1 (0.46) KDM4ESMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL6992696 0.81 CNR1 (0.45) KDM4ESMN1; SMN2MEN1KMT2AHTT
SCHEMBL25855377 0.80 RAB9A (0.50) KDM4ESMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL8545207 0.80 NPC1 (0.48) SMN1; SMN2MEN1KMT2AALDH1A1MAPT
SCHEMBL23126144 0.79 KDM4E (0.50) KDM4EF13A1SMN1; SMN2MEN1KMT2A
SCHEMBL19089782 0.79 POLB (0.57) KDM4EF13A1SMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11066526-B2 Method for cleaving amide bonds Galderma Holding SA (CH) 2021-07-20 US disclosed
US-11066526-B2 Method for cleaving amide bonds Galderma Holding SA (CH) 2021-07-20 US disclosed
US-20190010113-A1 METHOD FOR CLEAVING AMIDE BONDS GALDERMA S.A. (CH) 2019-01-10 US disclosed
CN-108884173-A METHOD FOR CLEAVING AMIDE BONDS 高德美股份公司 2018-11-23 CN disclosed
WO-2017114859-A1 METHOD FOR CLEAVING AMIDE BONDS GALDERMA S.A. (CH) 2017-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190010113-A1 METHOD FOR CLEAVING AMIDE BONDS DNPEP, NAAA, ASPH KDM4E 1693/4885F13A1 1144/4885SMN1; SMN2 3089/4885
US-11066526-B2 Method for cleaving amide bonds DNPEP, NAAA, ASPH KDM4E 1693/4885F13A1 1144/4885SMN1; SMN2 3089/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.